In the present study the chemopreventive activities of DFMO, the irreversible inhibitor of ornithine decarboxylase, and finasteride, the inhibitor of prostatic 5a-reductase, against the development of chemically induced prostate adenocarcinoma by methylnitrosourea/testosterone propionate in male Wistar rats were investigated. According to histological examination, oral administration of DFMO and finasteride, either alone or combined, for two months to MNU/TP-inoculated rats reduced the tumor incidence to 11.11%, 10% and 10%, respectively, compared to tumored controls (64.3%). DFMO and/or finasteride treatment resulted in significant reductions in the wet weight of the prostate gland and seminal vesicles and its ratio relative to the total body weight, as well as the levels of prostate total protein, DNA, RNA and DNA/RNA ratio, compared to tumored controls. However, the effect of the combined treatment was of no statistical significance compared to single DFMO or finasteride treatment, as demonstrated by the non-significant differences between the mean values of most of the studied parameters. The tumor chemopreventive activity and the prostate growth inhibitory effect of DFMO and finasteride were due to suppression of prostate polyamine synthesis. ANOVA test revealed that the relative weight of the prostate as well as blood and tissue polyamine levels could be used as significant endpoint biomarkers for DFMO and finasteride as cancer chemopreventive agents.
GriffithsK., MortonM.S.: Aspects of the cell biology of prostate cancer. In: Textbook of prostate cancer. Pathology, diagnosis and treatment, KaisaryA.V., MurphyG.P., DenisL., GriffithsK. (eds), pp 51–74, Martin Duntiz Ltd, London, 1999.
2.
MuradM., El-HosseinyS., AnwarM., MosaadM., TharwatW., EissaS.: Value of histological grading, nuclear DNA ploidy status and nucleolar organizer regions (AgNORs) count in predicting the biologic behaviour of prostatic adenocarcinoma. J Egypt Natl Cancer Inst, 8: 89–96, 1996.
3.
HestonW.D.W., KadmonD.: Alpha-difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. J Urol, 136: 944–948, 1986.
4.
SchenkelE., BerlaimontV., DuboisJ., Helson-CambierM., HanocqM.: Improved high-performance liquid chromatographic method for the determination of polyamines as their benzoylated derivatives: application to P388 cancer cells. J Chromatogr, 668: 189–197, 1995.
5.
SaydjariR., AlexanderR.W., UppJ.R., BarrancoS.C., TownsendC.M., ThompsonJ.C.: Differential sensitivity of different human tumors to inhibition of polyamine biosynthesis in vivo. Int J Cancer, 47: 44–48, 1991.
6.
JanneJ., HolttaE., KallioA., KapyahoK.: Role of polyamines and their metabolites in clinical medicine. Spec Top Endocrinol Metabol, 5: 227–293, 1983.
PorterC.W., SufrinJ.R.: Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res, 6: 525–542, 1986.
9.
SunkaraP.S., BaylinS.B., LukG.D.: Inhibitors of polyamine biosynthesis: cellular and in vivo effects on tumor proliferation. In: Inhibition of polyamine metabolism. Biological significance and basis for new therapies, McCannP.P., PeggA., SjoerdsmaA. (eds), pp 121–140, Academic Press, Orlando, FL, 1987.
10.
FujimotoS., IgarashiK., ShresthaR.D., MiyazakiM., OkuiK.: Antitumor effects of two polyamine antimetabolites combined with mitomycin C on human stomach cancer cells xenotransplanted into nude mice. Int J Cancer, 35: 821–825, 1985.
11.
TuttonP.J.M., BarklaD.H.: Comparison of the effects of an ornithine decarboxylase inhibitor on the intestinal epithelium and on intestinal tumors. Cancer Res, 46: 6091–6094, 1986.
12.
EinspahrJ.G., NelsonM.A., SabodaK., WarnekeJ., BowdenG.T., AlbertsD.S.: Modulation of biologic endpoints by topical difluoromethyl-ornithine (DFMO) in subjects at high risk for non-melanoma skin cancer. Clin Cancer Res, 8: 149–155, 2002.
13.
RoehrbornC.G., BoyleP., BergnerD.: Serum prostate specific antigen and prostate volume predict long term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Pless Study Group. Urology, 54: 662–669, 1999.
14.
StonerE.: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 43: 284–292, 1994.
15.
CarlinJ.R., ChristofaloP., ArisonB.H., EllsworthR.E., RosegayA., MillerR.R., ChiuS.H., VandenHeuvelW.J.: Disposition and metabolism of finasteride in dogs. Drug Metab Dispos, 25: 100–109, 1997.
16.
BolognaM., MuziP., BiordiL., FestucciaC., VicentiniC.: Finasteride dose-dependently reduces the proliferation rate of LNCap human prostatic cancer line in vitro. Urology, 45: 282–290, 1995.
17.
HommaY., KanekoM., KondoY.: Inhibition of rat prostate carcinogenesis by a 5 alpha-reductase inhibitor, FK143. J Natl Cancer Inst, 89: 803–807, 1997.
18.
TsukamotoS., AkazaH., OnozawaM.: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 82: 531–537, 1998.
19.
FleshnerN.E., TrachtenbergJ.: Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol, 24(suppl 2): 106–112, 1993.
20.
FleshnerN.E., TrachtenbergJ.: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol, 154: 1642–1646, 1995.
21.
OrnsteinD.K., RaoG.S., JohnsonB., CharltonE.T., AndrioleG.L.: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology, 48: 901–905, 1996.
22.
BrufskyA., Fontaine RotheP., BerlaneK., RiekerP., JiroutekM., KaplanI., KaufmanD., KantoffP.: Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology, 49: 913–920, 1997.
23.
KirbyR., RobertsonC., TurkesA., GriffithsK., DenisL.J., BoyleP., AltweinJ., SchröderF.: Finasteride in association with either flutamide or goserelin as combination hormonal therapy in. patients with stage M1 carcinoma of the prostate gland. Prostate, 40: 105–114, 1999.
24.
BrawleyO.W., BarnesS., ParnesH.: The future of prostate cancer prevention. Ann N Y Acad Sci, 952: 145–152, 2001.
25.
BoslandM.C., ChungL.W.K., GreenbergN.M., HoS-M, IsaacsJ.T., LaneK., PeehlD.M., ThompsonT.C., Van SteenbruggeG.J., Van WeerdenW.M.: Recent advances in the development of animal and cell culture models for prostate cancer research. Urol Oncol, 2: 99–128, 1996.
26.
PeggA.E., McCannP.P.: Polyamine metabolism and function. Am J Physiol, 243: C212–C221, 1982.
27.
PagetG.E., BarnesJ.M.: Evaluation of drug activities. In: Pharmacometrics, vol I, LaurenceD.R., BacharachA.L. (Eds), p 50, Academic Press, London, 1964.
28.
PollardM., LuckertP.H.: Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst, 77: 583–586, 1986.
29.
SaekiY., UeharaN., ShirakawaS.: Sensitive fluorimetric method for the determination of putrescine, spermidine and spermine by HPLC and its application to human blood. J Chromatogr, 145: 221–229, 1978.
30.
LoserC., WunderlichU., FolschU.R.: Reversed-phase liquid chromatographic separation and simultaneous fluorimetric detection of polyamines and their monoacetyl derivatives in human and animal urine, serum and tissue samples: an improved, rapid and sensitive method for routine application. J Chromatogr, 430: 249–262, 1988.
31.
RedmondJ.W., TsengA.: High-pressure liquid chromatographic determination of putrescine, cadaverine, spermidine and spermine. J Chromatogr, 170: 479–481, 1979.
32.
YalowR., BersonS.: Introduction and general considerations. In: Principles of competitive protein binding assays, OdellW.D., DaughdayW.H. (eds), pp 1–19, JB Lippincott Co, Philadelphia, 1971.
33.
BradfordM.M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72: 248–254, 1976.
34.
SchneiderW.C.: Phosphorus compounds in animal tissues I. Extraction and estimation of deoxypentose nucleic acid and of pentose nucleic acid. J Biol Chem, 161: 293–298, 1945.
35.
DischeZ., SchwartzK.: Estimation of nucleic acids. In: Methods of biochemical analysis, Vol I, GlickD. (ed), p 299, Inter-science Publishers Inc, New York, 1954.
36.
DischeZ.: Determination of pentoses. In: Methods in enzymology, Vol III, ColourickS.P., KaplanN.O. (eds), p 88, Academic Press Inc., New York, 1957.
KatayamaS., FialaE., ReddyB.S., RivensonA., SilvermanJ., WilliamsG.M., WeisburgerJ.H.: Prostate adenocarcinoma in rats: induction by 3, 2'-dimethyl-4-aminobiphenyl. J Natl Cancer Inst, 68: 867–873, 1982.
39.
PourP.M.: Prostate cancer induced in MRC rats by N-nitrosobis(2-oxopropyl)amine and N-nitrosobis(2-hydroxypropylamine). Carcinogenesis, 4: 49–55, 1983.
40.
PollardM., LuckertP.H.: Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system. Prostate, 11: 219–227, 1987.
41.
OtaD.M., GrossieB., AjaniJ.A., StephensC., NishiokaK.: Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer, 38: 245–249, 1986.
42.
ChamaillardL., QuemenerV.C., MoulinouxJ.P.: Synergistic activation of macrophage activity by polyamine deprivation and cyclophosphamide. Anticancer Res, 17: 1059–1066, 1997.
43.
HestonW.D.W.: Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv, 11: 217–238, 1991.
44.
PeggA.E.: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res, 48: 759–774, 1988.
45.
DanzinC., ClaverieN., WagnerJ., GroveJ., Koch-WeserJ.: Effect of prostatic growth of 2-difluoromethylornithine, an effective inhibitor of ornithine decarboxylase. Biochem J, 202: 175–181, 1982.
46.
NarayanP., TewariA., JacobG., MahmoudI., GajendranV., PrestiJ.: Differential suppression of serum prostatic acid phosphatase and prostate-specific antigen by 5-alpha-reductase inhibitor. Br J Urology, 75: 642–646, 1995.
47.
CaldareraC.M., MoruzziM.S., BarbiroliB., MoruzziG.: Spermine and spermidine of the prostate gland of orchiectomized rats and their effect on RNA polymerase activity. Biochem Biophys Res Commun, 33: 266–271, 1968.
48.
PeggA.E., LockwoodD.H., Williams-AshmanH.G.: Concentrations of putrescine and polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem J, 117: 17–31, 1970.
49.
PajunenA.E., IsomaaV.V., JanneO.A., BardinC.W.: Androgenic regulation of ornithine decarboxylase activity in mouse kidney and its relationship to changes in cytosol and nuclear androgen receptor concentrations. J Biol Chem, 257: 8190–8198, 1982.
50.
TaborC.W., TaborH.: Polyamines. Ann Rev Biochem, 53: 749–790, 1984.
51.
PeggA.E.: Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J, 234: 249–262, 1986.
